A key ESG advantage comes from the lower energy process (saving up to 90% energy consumption) which avoids harsh processing conditions, thereby preserving the integrity and stability of sensitive drug payloads such as proteins.
Our expertise in formulations includes
· Lipid nanaoparticles (LNPs)
· Polymer nanoparticles (PNPs)
· Hybrid nanoparticles
· Polymer (PLGA, PLA, etc) microspheres
· Core/shell coacervates
· and many others……
Micropore’s proven scalable technology works from an initial experimental sample of 200 microlitres all the way up to over 1,000 liters/hour under GMP conditions. We offer a true partnership with our customers from discovery, through development and clinical trials, into full manufacturing. This includes support for DQ, IQ and OC as well as sanitisation and sterilisation protocols.
The company is headquartered in the UK, has subsidiaries in the USA and India and has local representation and support in Japan, South Korea, Australia and New Zealand.